Mutations in superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by the loss of upper and lower motor neurons in the brain and spinal cord. It has been suggested that the toxicity of mutant SOD1 results from its misfolding and accumulation on the cytoplasmic faces of intracellular organelles, including the mitochondria and endoplasmic reticulum (ER) of ALS-affected tissues. Recently, macrophage migration inhibitory factor (MIF) was shown to directly inhibit the accumulation of misfolded SOD1 and its binding to intracellular membranes, but the role of endogenous MIF in modulating SOD1 misfolding in vivo remains unknown. To elucidate this role, we bred MIF-deficient mice with SOD1 G85R mice, which express a dismutase-inactive mutant of SOD1 and are considered a model of familial ALS. We found that the accumulation of misfolded SOD1, its association with mitochondrial and ER membranes, and the levels of sedimentable insoluble SOD1 aggregates were significantly higher in the spinal cords of SOD1
Mutations in superoxide dismutase (SOD1) cause amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease characterized by the loss of upper and lower motor neurons in the brain and spinal cord. It has been suggested that the toxicity of mutant SOD1 results from its misfolding and accumulation on the cytoplasmic faces of intracellular organelles, including the mitochondria and endoplasmic reticulum (ER) of ALS-affected tissues. Recently, macrophage migration inhibitory factor (MIF) was shown to directly inhibit the accumulation of misfolded SOD1 and its binding to intracellular membranes, but the role of endogenous MIF in modulating SOD1 misfolding in vivo remains unknown. To elucidate this role, we bred MIF-deficient mice with SOD1 G85R mice, which express a dismutase-inactive mutant of SOD1 and are considered a model of familial ALS. We found that the accumulation of misfolded SOD1, its association with mitochondrial and ER membranes, and the levels of sedimentable insoluble SOD1 aggregates were significantly higher in the spinal cords of SOD1
G85R -MIF
−/− mice than in their SOD1 G85R -MIF +/+ littermates. Moreover, increasing MIF expression in neuronal cultures inhibited the accumulation of misfolded SOD1 and rescued from mutant SOD1-induced cell death. In contrast, the complete elimination of endogenous MIF accelerated disease onset and late disease progression and shortened the lifespan of the SOD1 G85R mutant mice. These findings indicate that MIF plays a significant role in the folding and misfolding of SOD1 in vivo, and they have implications for the potential therapeutic role of upregulating MIF within the nervous system to modulate the selective accumulation of misfolded SOD1.
ALS | mutant SOD1 mouse | mutant SOD1 | misfolded SOD1 | MIF A myotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a selective loss of upper and lower motor neurons in the brain and spinal cord. Most cases of ALS are sporadic and lack any apparent genetic linkage, but 10% of cases are dominantly inherited, known as familial ALS (fALS) (1) . Of these familial cases, ∼20% have been attributed to mutations in a gene encoding for the ubiquitous cytoplasmic copper/ zinc superoxide dismutase (SOD1) (2) , and overexpression of the human mutant SOD1 in mouse models of fALS invariably results in motor neuron loss, muscle wasting, and hindlimb paralysis (3) .
Although the mechanism underlying SOD1-mediated toxicity is still unknown, many of the pathways that were hypothesized to underlie motor neuron degeneration in ALS involve damage incurred by the accumulation of misfolded SOD1 (4), as determined by using antibodies that recognize epitopes unavailable in the natively folded protein, and that bind preferentially or exclusively to misfolded conformers (5) (6) (7) .
Whereas the wild-type (WT) SOD1 is a ubiquitous cytoplasmic protein, a common feature of the SOD1 mutants is that they are localized to the mitochondria (8) (9) (10) (11) (12) (13) and/or endoplasmic reticulum (ER) (14) (15) (16) (17) , specifically in nervous system tissues. For instance, an association between mutant SOD1 and the ER has been implicated in the induction of ER stress (14-17), and misfolded mutant SOD1 has been found in fractions enriched for mitochondria derived from ALS-affected tissues, but not from unaffected ones (8, 10, 12, 13, 18, 19) . In addition, misfolded mutant SOD1 in its nonaggregated, soluble form has been found deposited on the cytoplasmic face of the outer membrane of spinal cord mitochondria (10, 12) , and this deposition was accompanied by altered mitochondrial shape and distribution (19) . These phenomena may be caused, at least in part, by binding of misfolded SOD1 directly to the mitochondrial voltage-dependent anion channel 1 (VDAC1), because such binding inhibits the ability of VDAC1 to transfer adenine nucleotides across the outer mitochondrial membrane (9) . Another possible cause is an interaction between misfolded SOD1 and other components in the outer membrane of the mitochondria, including Bcl-2 (20) and the protein import machinery (21) .
The molecular determinants that underlie the selective accumulation and binding of misfolded mutant SOD1 to the spinal cord mitochondria and ER remain unknown; however, we recently found that macrophage migration inhibitory factor (MIF) acts as a cytosolic chaperone that inhibits mutant SOD1 misfolding onto the mitochondria and ER, with extremely low MIF levels within the cytosol of motor neurons (22) .
MIF knockout (KO) mice, in which exons 2 and 3 of MIF are disrupted (23), did not develop obvious phenotypes when backcrossed onto a C57BL6 background (24) . In the present study, we used these MIF KO mice and the transgenic mutant SOD1 G85R mice (25) to study how endogenous MIF affects the course of Significance Amyotrophic lateral sclerosis (ALS) can be caused by mutations in superoxide dismutase (SOD1), which lead to the accumulation of misfolded SOD1 proteins and to the death of motor neurons. Here we show that endogenous macrophage migration inhibitory factor (MIF) acts as a chaperone for misfolded SOD1 in vivo, because completely eliminating MIF in a mutant SOD1 mouse model of familial ALS enhanced the accumulation of misfolded SOD1, accelerated disease onset and late disease progression, and shortened the lifespan of mice expressing mutant SOD1. This study thus sheds light on the important implications of modulating MIF levels and provides insight into the potential therapeutic role of MIF in suppressing the selective accumulation of misfolded SOD1 in ALS. disease and the accumulation and localization of misfolded SOD1. We report here that overexpression of MIF in neuronal cultures suppresses the accumulation of misfolded SOD1 and rescues from mutant SOD1-induced cell death. In contrast, completely eliminating MIF significantly enhances the accumulation of misfolded SOD1 and its association with mitochondrial and ER membranes and ultimately accelerates disease onset and decreases survival in SOD1 G85R mice.
Results
Increased MIF Expression Suppresses the Accumulation of Misfolded SOD1 and Enhances the Survival of Neurons Expressing Mutant SOD1
G93A . To test in vitro whether increased synthesis of MIF can prevent the accumulation of misfolded SOD1 and protect against its toxicity in neurons, human SH-SY5Y neuroblastoma cells were transfected to express the human WT (SOD1 WT ) or mutant (SOD1 G93A ) SOD1 transgenes, with or without cotransfection with a plasmid encoding for the human MIF. The accumulation of misfolded SOD1 was detected by immunoprecipitation (IP) with B8H10, a monoclonal antibody that recognizes epitopes within exon 3 that are exposed only on misfolding or denaturation of SOD1 (6, 26) and thus allows the detection of misfolded SOD1 forms by IP or immunofluorescence. Cell survival was quantified with the XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assay or, in a different set of experiments (wherein GFP-tagged versions of SOD1 WT or SOD1 G93A were used), by counting cells with the Operetta High-Content Imaging System (PerkinElmer).
Whereas expressing SOD1 G93A without MIF resulted in the intracellular accumulation of misfolded SOD1, coexpressing it with MIF reduced the accumulation of misfolded SOD1 without affecting the overall level of SOD1 (Fig. 1A) . Concomitantly, expressing mutant SOD1
G93A without MIF reduced cell survival by ∼30% compared with the expression of SOD1 WT , which did not affect cell survival, whereas coexpressing it with MIF rescued the cells from this toxic effect (Fig. 1B) . Similar results were obtained when MIF was expressed in motor neuron-like NSC-34 cells in the presence of GFP-tagged versions of SOD1 WT or mutant SOD1 G93A ( Fig. 1 C and D) . To determine in vivo whether the accumulation of misfolded SOD1 alters the course and pathogenesis of fALS, we bred the dismutase-inactive SOD1 G85R transgenic mice with MIF −/− (KO) mice, which completely lack MIF expression (24) (Fig. S1 ). The SOD1 G85R mouse line used in this study (25) develops a slowly progressive adult-onset fatal paralysis, which results WT or SOD1 G93A , with or without cotransfection with MIF. At 48 h after transfection, the cells were nuclear-stained with DAPI and then segmented with the Operetta High-Content Imaging System, using the Find Nuclei method. (Scale bars: 200 μm.) (D) The number of cells was quantified using the Operetta system. Quantitative analysis from triplicates of different biological repeats (n = 3) was performed using Student's t test. ***P < 0.001. from the expression of the mutant SOD1 G85R . Importantly, levels of SOD1 G85R accumulation in these mice are similar to those of endogenous mouse SOD1, thus closely mimicking the levels of mutant SOD1 accumulation in human fALS patients.
We also determined the intracellular localization of MIF in the spinal cords of these mice. Endogenous MIF clearly colocalized with mutant SOD1 in the cytosol of some, but not all, spinal cord cell types (Fig. S2 ). For example, MIF accumulation was very low within spinal neuronal cells (Fig. S3 ), confirming our previous observations using rat spinal cord tissues (22) .
To test whether endogenous MIF inhibits the association of mutant SOD1 with intracellular membranes, we collected spinal cord or liver tissue specimens from SOD1 G85R /MIF −/− and SOD1 G85R /MIF +/+ mice at different stages of the disease and isolated the mitochondrial and ER membranes (see schematic in Fig.  2A) . At disease onset, a significant amount of SOD1 G85R accumulated in mitochondrial (Fig. 2 B and C) and ER ( Fig. 2 E and F G85R mice, we used the B8H10 antibody to identify misfolded SOD1. An IP study (Fig. 3A) revealed that compared with their SOD1 G85R/ MIF +/+ littermates, SOD1 G85R /MIF −/− mice showed increased misfolded SOD1 accumulation in the spinal cord at all disease stages (Fig. 3B) , in the brain at the symptomatic and end stages (Fig. 3C) , and even (albeit less evidently) in the liver (Fig.  3D ). An immunofluorescence study revealed misfolded SOD1 accumulation in motor neurons and in other spinal cord cells already at the presymptomatic stage in SOD1 G85R /MIF −/− mice (Fig. 4 A-C and G), but not in their SOD1 
MIF Deletion Accelerates Disease Onset and Progression in Mutant SOD1
G85R Mice. After establishing that (i) MIF acts as a chaperone for misfolded SOD1 (22) and protects from mutant SOD1-induced cell death ( Fig. 1) , (ii) endogenous MIF inhibits the association of misfolded SOD1 with intracellular membranes ( 5C ). The progression from disease onset to an early disease point was not different between the two groups of mice (Fig. 5E ).
Discussion
One of the most important unsolved questions in ALS pathogenesis is what determines the selective, age-dependent degeneration of motor neurons. In cases related to mutant SOD1, such a degeneration is accompanied by the misfolding of mutant SOD1 and its association with intracellular membranes. We recently determined was also used to determine the presence and absence of MIF and the SOD1 levels remaining in the unbound fraction of each IP assay. Quantitative analysis of misfolded SOD1 was performed from duplicates or triplicates from different mice (between two and four mice for each genotype at each disease stage) using ImageJ software and Student's t test. **P < 0.01. that the association of mutant SOD1 with the mitochondria and ER can be suppressed by cytosolic MIF, which inhibits the accumulation of misfolded SOD1 (22) . In addition, we have shown that MIF levels are low within the cell bodies of motor neurons, and that increasing MIF levels extends the survival of motor neurons in culture. The low levels of MIF in motor neurons correlate with the accumulation of misfolded SOD1 species and with their increased association with various intracellular organelles.
In the present study, we demonstrate that completely eliminating the expression of endogenous MIF in vivo accelerated disease onset and late disease progression and shortened the lifespan of the SOD1 mutant mice. Importantly, the acceleration of disease onset was accompanied by the accumulation of misfolded SOD1 as early as the presymptomatic stage. In addition, the association of the mutant SOD1 with mitochondrial and ER membranes in the spinal cords of MIF-deficient mice was strongly increased, and the levels of sedimentable insoluble SOD1 aggregates were higher. Late disease progression was also accelerated in these mice, suggesting the involvement of endogenous MIF in preventing the toxicity of misfolded SOD1 within nonneuronal cells as well. In that context, the accumulation of misfolded SOD1 in glial cells has been proposed previously (27) , and its involvement in late disease progression is well established (4, 28) .
MIF is a 12-kDa protein that has been implicated in both extracellular and intracellular functions and is synthesized as a cytoplasmic protein (22) . The cytokine activity of MIF is achieved by posttranslational sequestration of the cytoplasmic MIF into vesicles, followed by its release, through an as-yet unidentified mechanism, in response to a variety of signals (29) . Intracellularly, MIF was previously shown to act as a chaperone protein (30) and as a thiol-protein oxidoreductase (31) .
Although MIF KO mice have been widely used in the context of various diseases, here we have studied the effects of MIF in a neurodegenerative disease model. Given the critical involvement of MIF in processes related to misfolding and neurodegeneration, as reported herein, it will be interesting to test whether MIF also can function as a protein modifier in other neurologic diseases in which misfolded proteins play a central role, such as Alzheimer's, Parkinson's, and Huntington's diseases.
Of note, a previous study has shown that reducing the levels of aggregated misfolded SOD1 by deleting cyclophilin D does not ameliorate the pathogenesis of ALS in mutant SOD1 mouse models (32) . Therefore, SOD1 toxicity in vivo appears to derive from the soluble form of the misfolded SOD1, rather than from its highly aggregated form. Indeed, we demonstrate here that reducing MIF levels accelerates disease onset and progression, and that this acceleration is accompanied by increased levels of the soluble misfolded SOD1, which accumulates and associates with mitochondrial and ER membranes. Altering the expression levels of other chaperones previously linked to SOD1, including hsp70, hsp90, hsp27, and aB-crystallin, failed to significantly affect the disease course in different mutant SOD1 mouse models (33-37); however, it was recently shown that overexpression of hsp110 in neurons extends the survival of SOD1 G85R -YFP and SOD1 G93A mice (38) . Importantly, there are only very few studies in which the course of disease was altered in the SOD1 model that we used here, which expresses mutant SOD1 at low levels similar to those of the endogenous protein, and in which disease onset was observed at approximately 10 mo, with a very rapid disease progression (25) . Here we propose that the reduced chaperone-like activity of MIF in motor neurons plays a pivotal role in the accumulation of misfolded SOD1 and its subsequent toxicity. In addition, with the recently proposed mechanism for cell-to-cell spread of misfolded SOD1 as a means of disease propagation (5, 39, 40) , chaperone activity by extracellular MIF may act to limit such spreading.
Finally, accumulation of misfolded SOD1 has been reported by several groups also in sporadic ALS (27, (41) (42) (43) (44) (45) (46) (47) , although other groups have reached the opposite conclusion (48) (49) (50) (51) . The identification of MIF as a cytosolic chaperone that stimulates the folding or refolding of misfolded SOD1 and inhibits the aggregation of mutant SOD1 in vivo suggests new avenues for therapy in ALS, mediated by increasing intracellular MIF levels in the nervous system.
Materials and Methods
Transgenic and KO Mice. Transgenic mice expressing the human SOD1 G85R were as described previously (25) . MIF KO mice have been developed in which exons 2 and 3 of MIF are disrupted (23) . These MIF KO mice, backcrossed onto a C57BL6 background (24) , were used in this study. Importantly, all mouse lines were on a pure C57BL6 background to eliminate confounding genetic influences. 10 females and 11 males). Mice were weighed weekly as an objective and unbiased measure of disease course. The time of disease onset was determined retrospectively as the time at which mice reached peak body weight, which is observed before any motor performance decline. The time of early disease was defined as the age at which the animals had lost 10% of their maximal weight. Disease end stage was defined by paralysis so severe that the animal could not right itself within 20 s when placed on its side, an endpoint frequently used for SOD1 mutant-expressing mice. Mice were genotyped by PCR of DNA extracted 
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-MIF , duration of early disease (from onset to 10% weight loss; P = 0.406) (E), and duration of late disease (from 10% weight loss to end stage; P < 0.01) (F). At each time point, the P value was determined by Student's t test. Error bars denote SD.
from a tail biopsy specimen. All mice were maintained using standard protocols in the animal facility of Ben-Gurion University of the Negev. All procedures involving animals were consistent with the requirements of the Animal Care and Use Committee of Ben-Gurion University of the Negev.
Statistics. Values are reported throughout as mean ± SEM. Comparisons of two datasets were performed using the Student's t test, after a normal distribution was confirmed by the Shapiro-Wilk normality test. Significance was set at a confidence level of 0.05. In all figures, *P < 0.05, **P < 0.01, and ***P < 0.001. All statistical analysis were performed with SigmaPlot 13.1 (Systat Software). SOD1 Aggregation Assay by Differential Extraction. The protocol for SOD1 aggregation by differential extraction was similar to that described previously (52) . Spinal cords were homogenized with a homogenizer in 1:10 (wt/vol) 1 TEN (10 mM Tris, 1 mM EDTA, and 100 mM NaCl), then mixed with an equal volume of 2× extraction buffer 1 (10 mM Tris, 1 mM EDTA, 100 mM NaCl, 1% Nonidet P-40, and 1× protease inhibitor mixture) and homogenized as described above. The resulting lysate was centrifuged for 5 min at 100,000 × g to separate the nonionic detergent-insoluble pellet (P1) from the supernatant (S1). S1 was then decanted and stored for analysis. P1 was resuspended in 200 μL of 1× extraction buffer 2 (10 mM Tris, 1 mM EDTA, 100 mM NaCl, 0.5% Nonidet P-40, and 1× protease inhibitor mixture) and then sonicated to resuspend. The extract was then centrifuged for 5 min at 100,000 × g in a Beckman Airfuge to separate the pellet (P2) from the supernatant. The P2 fraction was then resuspended in buffer 3 (10 mM Tris, 1 mM EDTA, 100 mM NaCl, 0.5% Nonidet P-40, 0.25% SDS, 0.5% deoxycholic acid, and 1× protease inhibitor mixture) by sonication and stored for analysis. Protein concentrations were measured in the S1 and P2 fractions by the BCA method (Pierce), according to the manufacturer's protocol. The proteins of S1 and P2 fractions were run in a 13% and a 15% SDS/PAGE gel, respectively.
Supporting Information
Mitochondria and ER Purification. Mitochondria were purified as described previously (22) . Spinal cords were homogenized on ice in 5 volumes of ice-cold homogenization buffer (HB), composed of 210 mM mannitol, 70 mM sucrose, 1 mM EDTA-(Tris), and 10 mM Tris·HCl pH 7.2. Homogenates were centrifuged at 1,000 × g for 10 min. The supernatants were then recovered, and the pellets were washed with half-volume HB and centrifuged at 1,000 × g for 5 min. The supernatants were pooled and centrifuged at 17,000 × g for 15 min to yield a crude mitochondrial pellet. The supernatant was used to make cytosolic and ER fractions by further centrifugation at 100,000 × g for 1 h. The mitochondria were gently resuspended in a 12-14% OptiPrep density gradient medium diluted in HB and centrifuged at 17,000 × g for 15 min. Myelin from the spinal cords was removed, and mitochondria were collected from the pellet, washed once with HB to remove the OptiPrep, and centrifuged at 17,000 × g for 15 min. Then the supernatant was discarded, and the pellet was resuspended in a small volume of HB. The proteins were quantified and run in a 13% SDS/PAGE gel. 
